Addressing the Commercial Importance of Supplementary Protection Certificates
As major patents on blockbuster drugs continue to expire, Chris Hayes, Senior Advisor, Intellectual Property Rights - Launched Products, Lundbeck, and Andrea Charles from Pharma IQ discuss how return-on-investment can be maximised and the key drivers for IP strategy. In this podcast, Hayes shares his thoughts on the commercial importance of Supplementary Protection Certficates (SPCs) and the pros and cons of SPCs versus data protection.
Have Your Say...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.